Quanterix has been granted a patent for a method and composition for quantitatively detecting antibodies to SARS-CoV-2 in human samples. The method involves contacting the sample with a spike polypeptide of the virus, assessing the detectable signal due to binding between the antibody and the polypeptide, and comparing it to a calibration data set. The calibration data set is generated using a chimeric antibody at various concentrations. GlobalData’s report on Quanterix gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Quanterix, laboratory automation robots was a key innovation area identified from patents. Quanterix's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Quantitative detection of human antibodies to sars-cov-2
A recently granted patent (Publication Number: US11686730B2) describes a method for quantitatively detecting antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the COVID-19 pandemic. The method involves several steps to assess the presence and concentration of antibodies in a human sample.
In the first step, a sample from a human is contacted with a SARS-CoV-2 S (spike) polypeptide or a fragment thereof. If antibodies to the SARS-CoV-2 S polypeptide are present in the sample, they will bind to the polypeptide. The binding between the antibody and the polypeptide generates a detectable signal, which is assessed in the second step.
To determine the amount, concentration, or level of the antibody in the sample, the detectable signal is compared to a calibration data set. This calibration data set is generated using a calibrator antibody that specifically binds to the SARS-CoV-2 S polypeptide at multiple concentrations or levels. The calibrator antibody used in the method is a chimeric antibody or a fragment thereof, consisting of a human constant region and a variable region component or a variable region from a non-human species. The calibration data set covers a range of concentrations or levels from about 0.001 ng/mL to about 10,000 ng/mL.
The method also includes additional steps to enhance the detection process. These steps involve using binders that can bind to the antibody-polypeptide complex and incorporating detectable labels. The second complex formed between the antibody, the SARS-CoV-2 S polypeptide, and the binder with a detectable label can be applied to a solid support surface, such as a microtiter plate or a microfluidic device.
Overall, this patented method provides a quantitative approach to detect antibodies to SARS-CoV-2 in human samples. It offers a reliable and accurate means of assessing the presence and concentration of these antibodies, which can be crucial for understanding immune responses to the virus and evaluating the effectiveness of vaccines and treatments.